scholarly journals Donepezil and α-synuclein Constipation: A 36 Month Follow-Up

2019 ◽  
pp. 1-7
Author(s):  
Charles M. Lepkowsky
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Acetylcholinesterase Inhibitor ◽  
Lewy Bodies ◽  
Neurocognitive Disorder ◽  
Apparent Reduction ◽  
Term Benefit

A case study is described in which four patients diagnosed at different stages of disease progression with the α‐synuclein or Lewy body disorders Parkinson’s disease (PD) and Neurocognitive Disorder with Lewy Bodies (NCDLB) were treated with the acetylcholinesterase inhibitor (AChEI) Donepezil to address the symptoms of constipation, obstipation and impaction. In all four patients, the use of Donepezil was associated with significant symptom reduction, which was maintained at intervals of six, twelve, eighteen and thirty-six months, with no apparent reduction in bowel motility, nor the emergence of any new symptoms. The results suggest that the AChEI Donepezil can have long-term benefit in reducing the symptoms of constipation, obstipation and impaction in patients with α‐synuclein disorders. Keywords: Neurocognitive Disorder with Lewy Bodies, Parkinson’s disease, constipation, Donepezil, acetylcholinesterase inhibitor

scholarly journals Donepezil and α-synuclein Constipation: A 48 Month Follow-Up

2021 ◽  
pp. 1-7
Author(s):  
Charles M. Lepkowsky
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Acetylcholinesterase Inhibitor ◽  
Lewy Bodies ◽  
Symptom Improvement ◽  
Neurocognitive Disorder ◽  
Apparent Reduction

In a case study, four patients diagnosed at different stages of disease progression with the α‐synuclein or Lewy body disorders Parkinson’s disease (PD) and Neurocognitive Disorder with Lewy Bodies (NCDLB) were treated with the acetylcholinesterase inhibitor (AChEI) Donepezil to address the symptoms of constipation, obstipation and impaction. The use of Donepezil was associated with significant symptom reduction for each of the four patients. In follow-up studies conducted at intervals of six, twelve, eighteen, thirty-six and forty-eight months, symptom improvement was maintained with no apparent reduction in bowel motility, nor the emergence of any new symptoms. The results suggest that the AChEI Donepezil can have long-term benefit in reducing the symptoms of constipation, obstipation and impaction in patients with α-synuclein disorders. Keywords: Neurocognitive Disorder with Lewy Bodies, Parkinson’s disease, constipation, Donepezil, acetylcholinesterase inhibitor

scholarly journals Donepezil for α‐synuclein Constipation: An 18 Month Follow-Up

2018 ◽  
Vol 1 (1) ◽  
pp. 1-4 ◽  
Author(s):  
Charles M. Lepkowsky
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Acetylcholinesterase Inhibitor ◽  
Lewy Bodies ◽  
Neurocognitive Disorder ◽  
Apparent Reduction ◽  
Symptom Status ◽  
Term Benefit

In a series of case studies, four patients diagnosed with the α‐synuclein or “Lewy body” disorders Parkinson’s disease (PD) and Neurocognitive Disorder with Lewy Bodies (NCDLB) at different stages of disease progression were treated for the symptoms of constipation, obstipation, and impaction with the acetylcholinesterase inhibitor (AChEI) Donepezil. Initial findings indicated that the use of Donepezil was associated with significant symptom reduction. The symptom status of each of the four patients was reviewed at six and twelve month intervals, with no apparent reduction in bowel motility, nor the emergence of any new symptoms. After eighteen months, the symptom status of each of the four patients was again assessed. Evaluation of the results suggests that the AChEI Donepezil may have long-term benefit for relieving the symptoms of constipation, obstipation and impaction in patients with α‐synuclein disorders. Keywords: Neurocognitive Disorder with Lewy Bodies, Parkinson’s disease, constipation, Donepezil, acetylcholinesterase inhibitor

scholarly journals Extradural Motor Cortex Stimulation in Parkinson’s Disease: Long-Term Clinical Outcome

2021 ◽  
Vol 11 (4) ◽  
pp. 416
Author(s):  
Carla Piano ◽  
Francesco Bove ◽  
Delia Mulas ◽  
Enrico Di Stasio ◽  
Alfonso Fasano ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Motor Cortex ◽  
Clinical Outcome ◽  
Motor Cortex Stimulation ◽  
Dopaminergic Therapy

Previous investigations have reported on the motor benefits and safety of chronic extradural motor cortex stimulation (EMCS) for patients with Parkinson’s disease (PD), but studies addressing the long-term clinical outcome are still lacking. In this study, nine consecutive PD patients who underwent EMCS were prospectively recruited, with a mean follow-up time of 5.1 ± 2.5 years. As compared to the preoperatory baseline, the Unified Parkinson’s Disease Rating Scale (UPDRS)-III in the off-medication condition significantly decreased by 13.8% at 12 months, 16.1% at 18 months, 18.4% at 24 months, 21% at 36 months, 15.6% at 60 months, and 8.6% at 72 months. The UPDRS-IV decreased by 30.8% at 12 months, 22.1% at 24 months, 25% at 60 months, and 36.5% at 72 months. Dopaminergic therapy showed a progressive reduction, significant at 60 months (11.8%). Quality of life improved by 18.0% at 12 months, and 22.4% at 60 months. No surgical complication, cognitive or behavioral change occurred. The only adverse event reported was an infection of the implantable pulse generator pocket. Even in the long-term follow-up, EMCS was shown to be a safe and effective treatment option in PD patients, resulting in improvements in motor symptoms and quality of life, and reductions in motor complications and dopaminergic therapy.

Long term follow-up in advanced Parkinson’s disease treated with DBS of the subthalamic nucleus

2021 ◽  
Author(s):  
Maria Antonietta Volonté ◽  
Giacomo Clarizio ◽  
Sebastiano Galantucci ◽  
Pietro Giuseppe Scamarcia ◽  
Rosalinda Cardamone ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Subthalamic Nucleus ◽  
Advanced Parkinson’S Disease ◽  
Long Term Follow Up

scholarly journals MMSE and MoCA in Parkinson’s disease and dementia with Lewy bodies: a multicenter 1-year follow-up study

2016 ◽  
Vol 123 (4) ◽  
pp. 431-438 ◽  
Author(s):  
Roberta Biundo ◽  
L. Weis ◽  
S. Bostantjopoulou ◽  
E. Stefanova ◽  
C. Falup-Pecurariu ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Dementia With Lewy Bodies ◽  
Lewy Bodies ◽  
Follow Up Study

Congenital erythropoietic porphyria and Parkinson's disease: clinical association in a patient with a long-term follow-up

2011 ◽  
Vol 21 (4) ◽  
pp. 613-614 ◽  
Author(s):  
Esteve Darwich ◽  
Antonio Guilabert ◽  
Azahara Aceituno ◽  
Natàlia Mas ◽  
Jordi To-Figueras ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Congenital Erythropoietic Porphyria ◽  
Long Term Follow Up

Long-Term Follow-Up Results of Stereotactic Adrenal Medullary Transplantation in Parkinson's Disease

1994 ◽  
Vol 62 (1-4) ◽  
pp. 141-147 ◽  
Author(s):  
Sang Sup Chung ◽  
Yong Gou Park ◽  
Jin Woo Chang ◽  
Joon Cho
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Long Term Follow Up

Long-term follow-up results of selective VIM-thalamotomy

1986 ◽  
Vol 65 (3) ◽  
pp. 296-302 ◽  
Author(s):  
Yoshishige Nagaseki ◽  
Tohru Shibazaki ◽  
Tatsuo Hirai ◽  
Yasuhiro Kawashima ◽  
Masafumi Hirato ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Essential Tremor ◽  
The Other ◽  
Content Type ◽  
Early Results ◽  
Initial Surgery ◽  
Long Term Follow Up

✓ The authors report the results of a long-term follow-up study of the effects of the physiologically defined selective VIM (nucleus ventralis intermedius)-thalamotomy on tremor of Parkinson's disease in 27 patients and essential tremor in 16 patients. The follow-up period ranged from 3.25 to 10 years (mean 6.58 years). In 43 patients a total of 50 operations (including four bilateral operations and three reoperations) were carried out. The early (2 to 4 weeks after surgery) and late effects on the tremors were determined clinically and electromyographically. Fourteen parkinsonian cases were treated with minimal lesions (about 40 cu mm). Their late results were very similar to the early results: in 10, the tremors were completely abolished, three had a slight residual tremor, and one underwent reoperation 3 months after the first surgery. Eleven essential tremor cases were treated with minimal lesions. Six of these tremors were completely abolished, four patients had slight residual tremors, and one patient with a recurrence underwent reoperation 2 years after the initial surgery. In these 23 successful operations with minimal lesions (excluding two cases with reoperation), the tremor was abolished without discernible long-lasting side effects. The other 23 operations on 16 patients with Parkinson's disease (including one reoperation) and on seven with essential tremor (one of whom also had a minimal lesion on the other side) involved relatively large lesions. In this group, the surgery was successful in almost every case. It was concluded that radiographically and physiologically monitored selective VIM-thalamotomy for parkinsonian and essential tremor is effective even when lesioning is minimal. Moreover, the beneficial effect is maintained over a long period of time.

Sign in / Sign up

Export Citation Format

Share Document